Analysts’ Top Healthcare Picks: ABBV, LIVN

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (NYSE: ABBV) and LivaNova PLC (NASDAQ: LIVN) with bullish sentiments.

AbbVie (NYSE: ABBV)

Jefferies analyst Michael Yee maintained a Buy rating on AbbVie (NYSE: ABBV) today and set a price target of $107. The company’s shares opened today at $89.39, close to its 52-week high of $89.69.

According to TipRanks.com, Yee is a 5-star analyst with an average return of 11.3% and a 63.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Arbutus Biopharma Corporation, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on AbbVie is Moderate Buy and the average price target is $90.29, representing a 1.0% upside.

In a report issued on September 5, Piper Jaffray also reiterated a Buy rating on the stock with a $85 price target.
LivaNova PLC (NASDAQ: LIVN)

Jefferies analyst Raj Denhoy maintained a Buy rating on LivaNova PLC (NASDAQ: LIVN) today and set a price target of $80. The company’s shares opened today at $68.67, close to its 52-week high of $69.29.

According to TipRanks.com, Denhoy is a top 100 analyst with an average return of 14.8% and a 67.8% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on LivaNova PLC is Moderate Buy and the average price target is $73.75, representing a 7.4% upside.

In a report issued on September 12, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $75 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.